Siglec-15 promotes progression of clear renal cell carcinoma

Clear cell renal cell carcinoma(ccRCC)is the most common subtype of renal cell carcinoma,accounting for approximately 80%of cases.Although most patients in the early stages of ccRCC can be cured by surgery,ccRCC is often in the advanced stage when patients are diagnosed,.with:>30%of the patients presenting with distant metastases at the time of diagnosis.For ccRCC patients with distant metastases,the 5-year survival is only 12%.Immunotherapy selectively corrects tumor microenviron-ment(TME)immunity,which is of great significance for patients with advanced ccRCC.